Indeed, the concentration of tau in plasma is approximately 100-fold lower than that in CSF, and, given the limited amount of tau aggregates in brains from DM1 patients, it is possible that even tools such as SiMoA might not be sensitive enough to detect extremely small amounts of this analyte. This evidence concerns the gene MAPT and myotonic dystrophy type 1.